News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 12, 2022
Physicochemical properties of peptides can provide key insights to potential success of oral delivery BOONTON, N.J., Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company...
- Sep 07, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Sep 01, 2022
Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused...
- Aug 10, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET Corporate Highlights Celebrated 10th anniversary as a life science focused specialty finance...
- Aug 09, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET DALLAS, Aug. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
- Aug 03, 2022
Article describes Enteris' strengths and scalability in working with highly potent active pharmaceutical ingredients BOONTON, N.J., August 3, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- Jul 14, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jul 13, 2022
Since 2012, SWK Holdings has completed financings with 46 life sciences companies, deploying $650 million of capital Second Quarter 2022 Financial Results to be Announced in August DALLAS, July...
- Jun 27, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company catering to small-and mid-sized commercial-stage companies, announced today its addition to the Russell...
- Jun 13, 2022
Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal...
- Jun 07, 2022
Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says BOONTON, N.J., June 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- May 26, 2022
Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help comfort sick children as they undergo...
- May 19, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced today that...
- May 11, 2022
In the news release, SWK Holdings Corporation Announces Financial Results for First Quarter 2022, issued 11-May-2022 by SWK Holdings Corporation over PR Newswire, we are advised by the company...
- May 10, 2022
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS, May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
- May 04, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 12, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 04, 2022
Article describes unique features of Enteris' Peptelligence® and ProPerma® peptide and small molecule oral delivery technology BOONTON, N.J., April 4, 2022 /PRNewswire/ -- Enteris BioPharma,...
- Mar 28, 2022
Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter
- Mar 25, 2022
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today they have closed a significant round of growth funding from the...
- Mar 23, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Mar 07, 2022
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
- Mar 07, 2022Paper examines barriers to achieving optimal content uniformity with HPAPIs and the techniques manufacturers should use with low-dose drug products
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 02, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Feb 16, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the reconstitution of the...
- Feb 15, 2022Six feasibility programs underway for oral tablet formulations developed with Enteris' Peptelligence® and ProPerma® technology platforms
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Feb 09, 2022Fourth Quarter 2021 Financial Results to be Announced in March
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Jan 10, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 05, 2022
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board of directors (the "Special Committee") has concluded its...
- Jan 05, 2022Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Dec 27, 2021Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms
REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced...
- Dec 20, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Dec 09, 2021Fourth milestone payment triggered by successful completion of process technology transfer related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Nov 24, 2021Announces Formation of Special Committee
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on November 23, 2021, it received a non-binding proposal from funds managed by Carlson Capital, L.P. ("Carlson") to...
- Nov 17, 2021Paper Discusses the 505(b)(2) Pathway as a Vehicle for Innovation and Product Differentiation
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 12, 2021Conference Call and Live Audio Webcast Scheduled for Monday, November 15, 2021 at 10:00 a.m. ET
Corporate Updates Conclusion of strategic review process with SWK to focus on specialty finance receivables business SWK evaluating ongoing dividend and additional leverage Third Quarter 2021...
- Nov 02, 2021Paper Examines the Opportunities and Challenges in Working with High Potency APIs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 01, 2021Commitment to focus on and grow SWK's core specialty finance business going forward
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an...
- Oct 26, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Oct 13, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Oct 04, 2021Data indicates optimized Peptelligence oral leuprolide formulation delivers comparable or greater drug levels than subcutaneous or depot injection
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Aug 23, 2021Enteris recognized for the third consecutive year in Pharmaceutical Company category
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Aug 16, 2021Conference Call and Live Audio Webcast Scheduled for Tuesday, August 17, 2021 at 10:00 a.m. ET
Corporate Updates The Specialty Finance Receivables and Pharmaceutical Development segments each reported strong quarters Closed a $5.0 million synthetic royalty transaction in April 2021 and a...
- Jul 19, 2021Second Quarter 2021 Financial Results to be Announced in August
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Jun 23, 2021
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Jun 15, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 11, 2021Third milestone payment related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Jun 07, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 17, 2021Conference Call and Live Audio Webcast Scheduled for Tuesday, May 18, 2021 at 10:00 a.m. ET
Corporate Updates YTD SWK has closed two financings totaling up to $14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business...
- May 17, 2021
The Board of Directors (the "Board") of SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") and its controlling stockholder, funds affiliated with Carlson Capital, L.P. ("Carlson"),...
- May 03, 2021CDMO Business Driven by Custom Solutions from Bench to Market for the Development and Manufacture of Difficult to Formulate Drugs and Highly Potent Compounds
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 06, 2021
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on April 5, 2021, a Special Committee (the "Special Committee") of the Company's Board of Directors received a...
- Mar 31, 2021Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020
Corporate Highlights Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an...
- Mar 24, 2021
Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, today announced the completion of a major new round of growth financing with SWK Holdings Corporation (Nasdaq:
- Mar 16, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 15, 2021
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Winston Black, Chairman...
- Feb 16, 2021Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an update on the progress and...
- Jan 12, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 07, 2021Enteris poised to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma™ platforms
Rajiv Khosla, Ph.D., named Chief Executive Officer Gary A. Shangold, M.D., appointed Chief Medical Officer Received two milestone payments totaling $5 million from Cara Therapeutics per licensing...
- Jan 04, 2021
Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delivery solutions and SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty...
- Dec 24, 2020Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Dec 18, 2020
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to...
- Dec 17, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 13, 2020Conference Call and Live Audio Webcast Scheduled for Monday, November 16, 2020, at 10:00 a.m. ET
Corporate Highlights Enteris BioPharma, Inc., ("Enteris") a wholly-owned subsidiary of SWK Holdings, recognized $2.5 million in milestone revenue under the license agreement with Cara...
- Nov 11, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in...
- Oct 29, 2020Third Quarter 2020 Financial Results to be Announced in November 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...
- Oct 28, 2020
UK-based ostomy specialist Trio Healthcare has secured a multi-million-pound financing from US specialised finance company, SWK Holdings Corporation, as the company targets significant domestic...
- Oct 27, 2020First of multiple anticipated milestone payments related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Sep 15, 2020Presentations to Highlight Corporate Achievements and Investment Strategy
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will present at two...
- Sep 15, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Sep 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Sep 09, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in the...
- Aug 31, 2020PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and...
- Aug 17, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, 2020, at 10:00 a.m. ET
Corporate Highlights Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma Repurchased $1.0 million of common stock during the three-month span ended June 30, 2020 SWK...
- Aug 14, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, at 10:00 a.m. ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020,...
- Jun 29, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today its addition to the broad-market Russell 3000® Index, the Russell 2000® Index and the...
- Jun 23, 2020Presentation Scheduled for June 25, 2020, at 11:30 a.m., ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today that Chairman and CEO Winston Black will present via webcast at the Life Sciences...
- Jun 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 02, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 14, 2020Conference Call and Live Audio Webcast Scheduled for Friday, May 15, 2020, at 10:00 a.m. ET
Corporate Highlights Core specialty finance segment generated an 11.3% adjusted ROIC, and yielding assets increased to $179.2 million, a 15.7% increase in comparison to the quarter ended March 31,...
- May 04, 2020Accomplished Industry Executive Brings Extensive Business Development Experience and Deep Knowledge of Drug Delivery Technology to Enteris
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 30, 2020Transformative 2019 Underscored by Strong Finance Results and Enteris BioPharma Acquisition
Corporate Highlights Core specialty finance segment generated a 12.6% adjusted ROIC and yielding assets increased 4.8% year over year to $175.1 million Closed Enteris Biopharma acquisition SWK...
- Mar 26, 2020SWK Holdings Expects to Report Adjusted Earnings for Fourth Quarter and Year End 2019 of $4.3 to $4.7 million and $21.0 to $21.4 million, respectively
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today announced its preliminary revenue and...
- Feb 28, 2020Specialty Finance Portfolio Performance Highlights Strong Year, Underscored by Enteris BioPharma Acquisition and NASDAQ Uplisting
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...
- Feb 10, 2020Accomplished Biopharmaceutical and Drug Development Executive to Lead the Expansion of Enteris' External and Internal Development Programs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 27, 2020Enteris recognized for enhancing positive image of small businesses and service to customers
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 23, 2020Trading begins today, January 23, 2020, under the ticker symbol "SWKH"
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its shares of common stock will begin trading on the Nasdaq Capital Market beginning...
- Jan 21, 2020Trading to begin on January 23, 2020
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, today announced that its shares of common stock have been approved for listing on the...
- Nov 21, 2019Board Realignment Follows SWK's Acquisition of Enteris BioPharma
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that Winston Black, Chief Executive Officer of SWK, has been named...
- Nov 18, 2019
Corporate Highlights Acquired Enteris BioPharma, Inc. ("Enteris") a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology,...
- Sep 16, 2019Presentation Scheduled for Today, September 16, 2019, at 4:30 p.m., ET
Dallas, TX, September 16, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that CEO Winston Black, will...
- Sep 06, 2019
Dallas, TX, September 6, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors...
- Sep 03, 2019SWK Expands Board of Directors to Meet NASDAQ Listing Requirements
Dallas, TX – September 3, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today that the Company has...
- Aug 27, 2019SWK Holdings Corporation acquires 100% of Enteris’ equity
Dallas, TX and Boonton, NJ – August 27, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, and Enteris BioPharma,...
- Aug 12, 2019Total revenues of $5.7 million for the second quarter 2019 compared to $6.8 million for the second quarter 2018.
Dallas, TX, August 12, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2019 financial...
- May 15, 2019Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.
Dallas, TX, May 15, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2019 financial results.
- Mar 29, 2019Total revenues of approximately $26.0 million for the fiscal year 2018 compared to $37.5 million for the fiscal year 2017.
Dallas, TX, March 29, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year...
- Dec 06, 2018
Dallas, TX, December 6, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors...
- Nov 12, 2018Total revenues of approximately $5.9 million for the third quarter of 2018 compared to $5.5 million for the third quarter of 2017.
Dallas, TX, November 12, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its third quarter 2018 financial...
- Sep 19, 2018Total revenues of approximately $6.8 million for the second quarter of 2018 compared to $6.1 million for the second quarter of 2017.
Dallas, TX, August 10, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2018 financial...